PUBLIC COMPANY
saveInversago Pharma Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
- phase2Study of INV-202 in Patients With Obesity and Metabolic Syndrome
- phase1Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
- phase1A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
🐶 Hiring Signal
News
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 7d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 7d ago
comments(0)
5-min edit window · permanent after that